Furthermore, treatment with increasing concentrations of Ruxolitinib (0 to 600 nM) and LSD1i (GSK-LSD1, 0–600 nM) confirmed their high synergy to reduce cell growth (Fig. 3D) and to specifically induce apoptosis in Zeb2Tg ETP-ALL (Fig. 3F, G). Here, KDM1A is linked to acute lymphoblastic leukemia.